<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Wilke, Hansjochen</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">RAINBOW Study Shows Significant Benefits in OS and PFS in Western Patients with Gastric Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">The Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma [RAINBOW; NCT01170663] is an international double-blind Phase 3 study of patients with metastatic gastric or gastroesophageal junction adenocarcinoma. This article presents the results from the planned region 1 subgroup analysis [Wilke H et al. Ann Oncol. 2014 (abstr O-0006)] consisting of Europe, Israel, the United States, and Australia.</style></abstract><number><style face="normal" font="default" size="100%">22</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>